Laureate Pharma, Inc. has renewed its agreement with Cytogen Corp. for the cGMP manufacture of ProstaScint, Cytogen’s proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen’s proprietary linker chelator and aseptic filling services to support commercial ProstaScint requirements. Terms of the agreement were not disclosed...